Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Corcept (CORT) To Contact Him Directly To Discuss Their Options If you purchased or acquired Corcept stock and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognize ...

New York, New York--(Newsfile Corp. - February 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws.What Happened?On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension secondary to hypercorti ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ: CORT) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CORCEPT THERAPEUTICS INCORPORATED (CORT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER. ...

investigation on behalf of Apollo Global Management, Inc. ("Apollo†or the "Company†) (NYSE: APO) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN APOLLO GLOBAL MANAGEMENT, INC. (APO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your...## Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money – Contact Law ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ: CORT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CORCEPT THERAPEUTICS INCORPORATED (CORT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On December 31, 2025, Corcept announc. ...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] ...

Core Viewpoint - Corcept Therapeutics Inc. is under investigation for potentially misleading investors regarding the efficacy and commercial prospects of its drug relacorilant, following warnings from the FDA not to submit its application for approval [1][2][4]. Group 1: Company Performance and Market Impact - Corcept's shares have declined significantly, resulting in a loss of approximately $3.2 billion in market capitalization since December 2025 [2]. - The company had previously projected that its hypercortisolism business could grow from $3 billion to $5 billion in annual revenue within three to five years [3]. Group 2: Regulatory Communications and Investor Relations - On December 31, 2025, Corcept received a complete response letter (CRL) from the FDA, indicating that the agency could not reach a favorable benefit-risk assessment for relacorilant without additional evidence of effectiveness [4]. - A corrected CRL issued on January 28, 2026, revealed that the FDA had warned Corcept multiple times against submitting its application, contradicting the company's earlier statements about its communications with regulators [4]. Group 3: Legal Investigation - Hagens Berman is expanding its investigation to determine if Corcept misled investors regarding its communications with the FDA, as well as the efficacy and safety of relacorilant [5].

Core Viewpoint - Corcept Therapeutics faces significant setbacks regarding its proposed treatment for hypercortisolism, relacorilant, following warnings from the FDA not to submit its drug application, leading to a sharp decline in share price [1][2]. Company Developments - On January 30, 2026, Corcept shares dropped by $7.81, or 17%, after reports of FDA warnings against submitting the drug application [1]. - The company's market capitalization has decreased by $3.2 billion since December 30, 2025, following the receipt of a complete response letter (CRL) from the FDA [4]. FDA Communications - The FDA had previously issued a CRL indicating that it could not arrive at a favorable benefit-risk assessment for relacorilant without additional evidence of effectiveness [3]. - A corrected CRL dated January 28 revealed that the FDA had warned Corcept on multiple occasions about significant review issues if the application was submitted [3]. Investor Concerns - Hagens Berman, a law firm, is investigating whether Corcept misled investors regarding relacorilant's efficacy and the company's communications with the FDA [2][4]. - The firm is also analyzing if Corcept overstated its commercial and growth prospects for the hypercortisolism business, which was projected to grow from $3 billion to $5 billion in annual revenues within three to five years [3].

BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, announces that it is investigating potential securities law violations by Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept” or the “Company”), a company based in Redwood City, California. About the Investigation On December 31, 2025, Corcept issued a press release announcing that “U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New D ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated due to allegations of materially misleading business information issued to the investing public [1] Company Summary - Corcept Therapeutics Incorporated is facing scrutiny for potentially misleading information that may have affected its securities [1] - Shareholders who purchased Corcept securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]